Search

Objective: To develop a French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (Fr-sQOD) to assess the quality of life impairments of patients with olfactory dysfunction (OD). Methods: Patients with OD and controls were enrolled from 2 academic centers. Individuals completed the Fr-sQOD, an OD visual analog scale severity, and the French version of the sinonasal outcome tool-22 (SNOT-22). Cronbach α was used to measure the internal consistency of Fr-sQOD. The reliability and the external validity of Fr-sQOD were assessed through a test–retest approach and by correlating Fr-sQOD with SNOT-22 scores, respectively. The external validity was assessed by correlation analysis between Fr-sQOD and the result of an assessment of the severity of OD on a visual analog scale. Results: Eighty patients completed the evaluations. The internal consistency was adequate (Cronbach α.96), and the test–retest reliability was high in the entire cohort (rs = 0.877, P <.001). The correlation between Fr-sQOD total scores and the severity of OD was moderate but significant (rs = −0.431; P =.001) supporting an acceptable external validity. Patients with OD had a significantly higher score of Fr-sQOD than healthy individuals (P <.001), indicating a high internal validity. Conclusion: The Fr-sQOD is a reliable and valid self-administered tool in the evaluation of the impact of OD on quality of life of French-speaking patients. [ABSTRACT FROM AUTHOR]

CONCLUSION Prolonged intubation used in severe COVID-19 patients is associated with significant laryngeal disorders including laryngeal edema, posterior glottic stenosis, granuloma, laryngeal necrosis, or vocal fold insufficiency. • COVID-19 patients who were intubated >14 days mainly reported posterior glottic stenosis, posterior commissure hypertrophy or laryngeal diffuse edema, and granuloma 51.6 days after the hospital discharge. The number of intubation days was significantly higher in patients with posterior glottic stenosis (26.1 ± 9.4) compared with those presenting posterior commissure hypertrophy (11.5 ± 2.9) or granuloma (15.1 ± 5.8; I p i < 0.001). Keywords: complications; coronavirus; COVID-19; intubation; laryngeal; larynx; otolaryngology; SARS-CoV-2; stenosis; voice EN complications coronavirus COVID-19 intubation laryngeal larynx otolaryngology SARS-CoV-2 stenosis voice 779 784 6 08/17/23 20230901 NES 230901 Key Points • At the start of the pandemic, many COVID-19 patients were intubated more than 14 days in intensive care units. [Extracted from the article]

The worldwide spread of coronavirus disease (COVID-19) is associated with the emergence of many clinical pictures of the disease. Patients might have nose and throat symptoms, such as loss of [...]

Objective: To evaluate the evolution of voice quality in patients after type I‐VI transoral CO2 laser cordectomy (TLC) by using validated voice outcome measures over a 12‐month period. Study Design: Prospective uncontrolled study. Setting: Monocenter study. Methods: Patients with laryngeal carcinoma who were eligible for type I‐IV TLC were prospectively recruited from a tertiary medical center. The following outcomes were assessed throughout the 12‐month posttreatment period: Voice Handicap Index (VHI), GRBAS (grade of dysphonia, roughness, breathiness, asthenia, strain), maximal phonation time, fundamental frequency (F0), F0 standard deviation, percentage jitter, percentage shimmer, noise‐to‐harmonic ratio, and speech fluency. Analyses were performed considering 2 groups of cordectomies: type I‐III vs IV‐VI. Results: A total of 131 patients completed the evaluations, totaling 76 type I‐III and 55 type IV‐VI cordectomies. In type IV‐VI, breathiness and maximal phonation time significantly worsened from pretreatment to 1 month posttreatment (P <.05). In the type I‐III cordectomy group, VHI, shimmer, roughness, breathiness, and strain significantly improved from pretreatment to 3 months posttreatment, while VHI, F0 standard deviation, shimmer, jitter, grade of dysphonia, roughness, breathiness, and strain improved from baseline to 6 months. Assessments at 12 months posttreatment revealed significant improvements for VHI, shimmer, jitter, noise‐to‐harmonic ratio, grade of dysphonia, roughness, breathiness, and strain. In the type IV‐VI group, VHI significantly improved from baseline to 3, 6, and 12 months posttreatment. Strain improved at 6 and 12 months while roughness improved from baseline to 12 months. Maximal phonation time significantly worsened over the 12‐month evaluation period. Conclusion: The effect of TLC on voice quality depends on its type. VHI was identified as the most indicative tool of voice changes irrespective of TLC type. [ABSTRACT FROM AUTHOR]

Objectives/Hypothesis: To compare the 12‐month evolution of voice quality outcomes in patients who benefited from types 1–2 transoral CO2 laser cordectomy (TLC) for an early‐stage vocal fold squamous cell carcinoma (VFSCC). Study Design: Prospective uncontrolled study. Methods: Sixty patients with cT1 VFSCC were consecutively recruited from a single medical center. Thirty patients benefited from type 1 TLC, while type 2 TCL was performed in 30 patients. The following voice quality outcomes were evaluated at baseline, 3‐, 6‐, and 12‐month post‐TLC: voice handicap index (VHI), GRBAS, speech rate, maximum phonation time (MPT), and acoustic parameters. Voice quality evolution was compared between type 1 and type 2 TLC. Results: Fifty‐seven patients completed the evaluations. Type 1 TLC patients reported significant improvements of VHI, grade of dysphonia, and breathiness at 3‐, 6‐, and 12‐month post‐TLC. Speech rate and jitter values improved 6‐ and 12‐month post‐TLC. A few voice quality outcomes reported 3‐ or 6‐month post‐TLC improvements in type 2 TLC group, while VHI, grade of dysphonia improved at 6‐ and 12‐month post‐TLC. MPT significantly decreased at 6‐ and 12‐month post‐TLC, while there were no acoustic measurement changes in type 2 TLC. Conclusions: The effect of TLC on voice quality may depend on the type of TLC. Type 1 TLC was associated with faster voice quality improvements compared with type 2 TLC. VHI and dysphonia grade were identified as the most relevant tool of voice changes irrespective to the TLC type. Level of Evidence: 3 Laryngoscope, 132:1421–1426, 2022 [ABSTRACT FROM AUTHOR]

Objectives/Hypothesis: To investigate the surgical, oncological, and functional outcomes of transoral robotic surgery (TORS) for the treatment of supraglottic squamous cell carcinoma. Study Design: Retrospective chart review. Methods: The charts of patients treated by TORS supraglottic laryngectomy (SGL) in an academic medical center were reviewed. The following outcomes were studied according to the tumor location: average robotic setup and operative times, mean estimated blood loss, postoperative complications, need of tracheotomy, refeeding characteristics, mean hospital stay, need of neck dissection and adjuvant therapy, 5‐year local and regional controls, overall survival (OS), and disease‐free survival (DFS). Results: Seventy‐five patients underwent TORS SGL. Tumors were classified as cT1 (32%), cT2 (52%), and cT3 (16%). Average robotic setup and operative times and the mean estimated blood loss were 15 minutes, 55 minutes, and 20 mL, respectively. The mean follow‐up period ranged from 2 to 5 years. The 5‐year OS and DFS were 80.2% and 94.3%, respectively. Overall, 34.6% of patients received adjuvant radiotherapy. The majority of patients (92%) restarted an oral diet within 24 to 48 hours postsurgery. Transient tracheotomy was performed in 8% of patients. Postoperative hemorrhages occurred in 12 patients (16.0%), lengthening the hospital stay (mean = 6.8 days). There were no outcome differences regarding the tumor location. Conclusions: TORS is an effective and safe therapeutic approach for early‐ and intermediate‐stages cancers. Oncological outcomes may be quite similar to other surgical approaches, including transoral laser and open surgeries. Future randomized controlled studies are needed for comparing TORS SGL with other surgical procedures. Level of Evidence: 4 Laryngoscope, 131:1060–1065, 2021 [ABSTRACT FROM AUTHOR]